Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.
MKE, E., AKE, E., HA, M., N, A., AES, M., RSK, A., AOM, A., MM, E., H, O., & SFA, E. (2026). Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.. La Clinica terapeutica. https://doi.org/10.7417/CT.2026.2083
MKE E, AKE E, HA M, N A, AES M, RSK A, et al. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.. La Clinica terapeutica. 2026; doi: 10.7417/CT.2026.2083
MKE E, AKE E, HA M, et al. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.[J]. La Clinica terapeutica. 2026. DOI: 10.7417/CT.2026.2083.
@article{mke2026,
author = {Elganyny MKE and Elganyni AKE and Maskji HA and Ajaka N and Mishriki AES and Amin RSK and Abaza AOM and Elgokhy MM and Omair H and Esmaeil SFA},
title = {Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.},
journal = {La Clinica terapeutica},
year = {2026},
doi = {10.7417/CT.2026.2083},
note = {PMID: 42340790},
}
TY - JOUR AU - Elganyny MKE AU - Elganyni AKE AU - Maskji HA AU - Ajaka N AU - Mishriki AES AU - Amin RSK AU - Abaza AOM AU - Elgokhy MM AU - Omair H AU - Esmaeil SFA TI - Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis. T2 - La Clinica terapeutica PY - 2026 DO - 10.7417/CT.2026.2083 AN - PMID:42340790 ER -
BACKGROUND: Semaglutide, a GLP-1 receptor agonist, has demonstrated metabolic and renal benefits in diabetic populations. However, its efficacy and safety in non-diabetic individuals with obesity and chronic kidney disease (CKD) remain largely unstudied. Given the high cardiometabolic risk in this group and limited therapeutic options, evaluating semaglutide's role is crucial. OBJECTIVE: To assess the effects of semaglutide on body mass index (BMI), blood pressure, renal function (eGFR), and albuminuria in non-diabetic patients with obesity and CKD or hypertension. METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. A total of 580 studies were screened; 3 eligible studies (n=430 participants) were included. Data were extracted from a randomized controlled trial, a real-world observational dialysis study, and a large post hoc trial analysis. Fixed-effect meta-analysis models were applied to estimate pooled effects on BMI, systolic blood pressure (SBP), and renal outcomes. RESULTS: Semaglutide treatment significantly reduced BMI (mean reduction: Tuttle 18.3%, Apperloo 11.8%, Vanek 1.5%; P = 0.001), and improved hypertension control (SBP <130 mmHg: Apperloo 20.6%, Vanek 12.5%, Tuttle 17.6%; P < 0.02). Renal function also improved, with eGFR >30 ml/min/1.73m² increasing from baseline in all studies (Apperloo 65.8%, Vanek 4.83%, Tuttle 36.4%; P < 0.001). No publication bias was detected. CONCLUSIONS: Semaglutide is effective and well-tolerated in non-diabetic patients with obesity and CKD, resulting in significant weight loss, better blood pressure control, and improved renal parameters. These findings support its expanded use in non-diabetic CKD populations, including dialysis-dependent individuals.